AR013967A1 - UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE - Google Patents

UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE

Info

Publication number
AR013967A1
AR013967A1 ARP980104797A ARP980104797A AR013967A1 AR 013967 A1 AR013967 A1 AR 013967A1 AR P980104797 A ARP980104797 A AR P980104797A AR P980104797 A ARP980104797 A AR P980104797A AR 013967 A1 AR013967 A1 AR 013967A1
Authority
AR
Argentina
Prior art keywords
pellet
controlled
acid
fluor
oxo
Prior art date
Application number
ARP980104797A
Other languages
English (en)
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR013967A1 publication Critical patent/AR013967A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Formulaciones medicamentosas que contienen el ácido 1-ciclopropil-7-((S,S)- 2,8-diazabiciclo(4.3.0)non-8-il)-6-fluor-1,4-dihidro-8-metoxi-4-oxo-3-quinoloncarboxílico y/o sus sales farmacéuticamente aceptables del mismo y/o hidratos del mismo comosustancia activa, que liberan la sustancia activacontenida con una liberacion definida.
ARP980104797A 1997-09-25 1998-09-25 UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE AR013967A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19742243 1997-09-25

Publications (1)

Publication Number Publication Date
AR013967A1 true AR013967A1 (es) 2001-01-31

Family

ID=7843534

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980104797A AR013967A1 (es) 1997-09-25 1998-09-25 UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
ARP080100352A AR065072A2 (es) 1997-09-25 2008-01-29 Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo
ARP080100353A AR065073A2 (es) 1997-09-25 2008-01-29 Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP080100352A AR065072A2 (es) 1997-09-25 2008-01-29 Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo
ARP080100353A AR065073A2 (es) 1997-09-25 2008-01-29 Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo

Country Status (37)

Country Link
US (1) US6270799B1 (es)
EP (1) EP1017392B1 (es)
JP (2) JP2001517625A (es)
KR (1) KR100531065B1 (es)
CN (3) CN1895233A (es)
AR (3) AR013967A1 (es)
AT (1) ATE220547T1 (es)
AU (1) AU731693B2 (es)
BG (1) BG64745B1 (es)
BR (1) BR9812553B1 (es)
CA (1) CA2304135C (es)
CO (1) CO5011082A1 (es)
CZ (1) CZ293062B6 (es)
DE (1) DE59804823D1 (es)
DK (1) DK1017392T3 (es)
ES (1) ES2179533T3 (es)
GT (1) GT199800152A (es)
HK (1) HK1032010A1 (es)
HN (1) HN1998000144A (es)
HU (1) HU226583B1 (es)
ID (1) ID24259A (es)
IL (1) IL134591A0 (es)
MY (1) MY129437A (es)
NO (1) NO327492B1 (es)
NZ (1) NZ503538A (es)
PE (1) PE20000224A1 (es)
PL (1) PL192273B1 (es)
PT (1) PT1017392E (es)
SI (1) SI1017392T1 (es)
SK (1) SK283462B6 (es)
SV (1) SV1998000119A (es)
TR (1) TR200000752T2 (es)
TW (1) TW523412B (es)
UA (1) UA66812C2 (es)
UY (1) UY25192A1 (es)
WO (1) WO1999015172A1 (es)
ZA (1) ZA988718B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
AU2002236132A1 (en) * 2002-03-05 2003-09-16 Ranbaxy Laboratories Limited Modified release oral pharmaceutical composition
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
PL1691787T3 (pl) * 2003-12-04 2008-11-28 Pfizer Prod Inc Sposób wytwarzania farmaceutycznych systemów wielocząstkowych
GB2409204A (en) * 2003-12-19 2005-06-22 Reckitt Benckiser Nv Plasticized thermoplastic polymer
PT1868581E (pt) * 2005-04-11 2012-06-22 Abbott Lab Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis
CN1762357B (zh) * 2005-09-21 2010-12-08 深圳市天一时科技开发有限公司 一种莫西沙星口服药物制剂及其制备方法
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
EP2837376A3 (de) 2008-12-08 2015-03-25 ratiopharm GmbH Kompaktiertes Moxifloxacin
ITTO20110705A1 (it) * 2011-07-29 2013-01-30 Italiana Sint Spa Procedimento di preparazione della moxifloxacina cloridrato e relativi intermedi
KR20200077712A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 목시플록사신 고형 제제 및 이의 제조방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485770A (en) 1967-03-02 1969-12-23 Atlantic Richfield Co Olefin polymerization catalyst based on aluminum pyrolate
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036227A (en) 1973-04-25 1977-07-19 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
CH668187A5 (de) 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3868077D1 (de) 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
TW209865B (es) * 1992-01-10 1993-07-21 Bayer Ag
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5520920A (en) 1992-08-28 1996-05-28 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
JP3220331B2 (ja) 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5473103A (en) 1993-12-16 1995-12-05 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Biopolymers derived from hydrolyzable diacid fats
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use

Also Published As

Publication number Publication date
DE59804823D1 (de) 2002-08-22
PL192273B1 (pl) 2006-09-29
CO5011082A1 (es) 2001-02-28
HU226583B1 (hu) 2009-04-28
UY25192A1 (es) 2001-08-27
AU731693B2 (en) 2001-04-05
SK283462B6 (sk) 2003-08-05
CZ20001076A3 (cs) 2000-07-12
NO20001375L (no) 2000-03-16
CA2304135A1 (en) 1999-04-01
ZA988718B (en) 1999-04-01
HUP0003840A2 (hu) 2001-04-28
CN1178659C (zh) 2004-12-08
BR9812553A (pt) 2000-07-25
WO1999015172A1 (de) 1999-04-01
AU9348498A (en) 1999-04-12
ATE220547T1 (de) 2002-08-15
JP2010163455A (ja) 2010-07-29
NO20001375D0 (no) 2000-03-16
CN1271281A (zh) 2000-10-25
PT1017392E (pt) 2002-10-31
CZ293062B6 (cs) 2004-01-14
TR200000752T2 (tr) 2000-09-21
KR100531065B1 (ko) 2005-11-28
BG64745B1 (bg) 2006-02-28
GT199800152A (es) 2000-03-17
AR065072A2 (es) 2009-05-13
US6270799B1 (en) 2001-08-07
SI1017392T1 (en) 2002-12-31
DK1017392T3 (da) 2002-10-21
ES2179533T3 (es) 2003-01-16
BR9812553B1 (pt) 2010-06-01
CA2304135C (en) 2009-01-06
JP2001517625A (ja) 2001-10-09
SV1998000119A (es) 1999-03-02
CN1623533A (zh) 2005-06-08
MY129437A (en) 2007-04-30
PL339349A1 (en) 2000-12-18
KR20010024269A (ko) 2001-03-26
EP1017392B1 (de) 2002-07-17
BG104256A (en) 2000-12-29
HK1032010A1 (en) 2001-07-06
IL134591A0 (en) 2001-04-30
NO327492B1 (no) 2009-07-20
AR065073A2 (es) 2009-05-13
EP1017392A1 (de) 2000-07-12
TW523412B (en) 2003-03-11
SK4032000A3 (en) 2000-09-12
CN1895233A (zh) 2007-01-17
ID24259A (id) 2000-07-13
HUP0003840A3 (en) 2006-06-28
NZ503538A (en) 2001-03-30
HN1998000144A (es) 1999-06-02
PE20000224A1 (es) 2000-05-11
UA66812C2 (uk) 2004-06-15

Similar Documents

Publication Publication Date Title
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
SE9402431D0 (sv) New tablet formulation
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
AR012698A1 (es) Formulacion farmaceutica de omeprazol
ES2189803T3 (es) Procedimiento.
SV1996000109A (es) Nueva variante cristalina del cdch, procedimiento para su produccion y preparados farmaceuticos que la contienen ref. lea 31308-sv
ATE292453T1 (de) Antivirale arznei
AR002743A1 (es) Esmalte de unas, y la utilizacion de dicho esmalte para la preparacion de un medicamento para el tratamiento de onicomicosis.
PH27446A (en) Compound with gastric acid inhibitory effect
ES2103486T3 (es) Medicamentos que contienen acidos difosfonicos y sus sales.
HN1999000174A (es) Formulacion medicamentosa acuisa para administracion oral.
ECSP982679A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa
AR031846A1 (es) Combinacion de sustancias activas, medicamentos y formulaciones que la contienen, y uso de la misma para la preparacion de un medicamento para el tratamiento del dolor
AR029096A1 (es) Combinacion de sustancias activas que contiene montirelina y un compuesto de efecto opioide, medicamentos y formulaciones medicamentosas que contienen dicha combinacion y su uso para la preparacion de medicamentos para tratamiento del dolor
DE60029946D1 (de) Arzneimittel gegen glomerulosclerose
CU23150A3 (es) Formulacion de medicamento con liberacion controlada de sustancia activa
JO1881B1 (en) Formula II for multi unit disc calibration
GT199700112A (es) Nuevas microesferas farmaceuticas para administracion oral.
TH20600A (th) เบนซิมิดาโซลที่ถูกแทนที่ (Substitued benzinidazole), กรรมวิธีสำหรับการเตรียมสารนั้นและการใช้ทางเภสัชศาสตร์ของสารนั้น

Legal Events

Date Code Title Description
FG Grant, registration